All Oncology News

Results from the randomized phase II HOVON89 trial showed that nearly 40% of patients with low intermediate-1 risk myelodysplastic syndrome who were refractory to erythropoietin and granulocyte-colony stimulating factor experienced hematologic improvement with erythroid response after being treated with lenalidomide monotherapy.

The addition of chemotherapy, either adjuvant or induction, to concomitant chemoradiotherapy achieved a significantly high survival benefit for patients with locally advanced nasopharyngeal carcinoma.

The FDA has granted a priority review to a supplemental new drug application supporting the conversation of the accelerated approval of palbociclib (Ibrance) to a full approval for use in combination with letrozole as a frontline treatment for postmenopausal women with ER-positive, HER2-negative metastatic breast cancer.

The FDA has approved the marketing of AeroForm, a new system for soft tissue expansion in 2-stage breast reconstruction following mastectomy, and in the treatment of underdeveloped breasts and soft tissue deformities.

The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, welcomes Kenneth W. Hance, Ph.D., M.P.H., Director of Antibody Therapies, Immuno-Oncology & Combinations DPU at GlaxoSmithKline (GSK), as its first Visiting Professor from GSK at Wistar.

Osimertinib, an EGFR tyrosine kinase inhibitor (TKI), is quickly emerging as a therapeutic option for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who develop the acquired resistance mutation T790M.

The BCL-2 inhibitor venetoclax (Venclexta) demonstrated activity in one-fifth of patients with heavily pretreated multiple myeloma.

The phase II HERMIONE trial was halted after the antibody-drug conjugate MM-302 combined with trastuzumab failed to improve progression-free survival versus chemotherapy plus trastuzumab in patients with HER2-positive metastatic breast cancer who had previously received trastuzumab, pertuzumab, and ado-trastuzumab emtansine.

JCAR017 has received an FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory, aggressive large B-cell non-Hodgkin lymphoma.

Frontline therapy for patients with ALK-positive non–small cell lung cancer is poised to change in the coming years, as researchers continue to explore agents beyond crizotinib.

The neoadjuvant combination of CDK4/6 inhibitor abemaciclib plus anastrazole may represent a novel therapeutic option for patients with hormone receptor-positive, HER2-negative early breast cancer.

The FDA has granted a priority review to a new drug application for the PARP 1/2 inhibitor niraparib for use as a maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have responded to platinum-based chemotherapy.

The benefits of 2 FDA-approved daratumumab–based triplet regimens were sustained in long-term data from 2 pivotal phase III studies presented at the 2016 ASH Annual Meeting.

Entospletinib was well tolerated and demonstrated modest activity in patients with relapsed or refractory mantle cell lymphoma.

Patients diagnosed with head and neck or lung cancer are especially prone to feelings of distress, especially depression, and researchers in the Netherlands have found that using a gradual or “stepped” approach to providing psychosocial support not only improves their quality of life but is also cost-effective.

Patients with myeloproliferative disorders have a high symptom burden that significantly affects emotional status, quality of life, and functional ability.

Patients with intermediate/high-risk myelofibrosis had improved survival when treated long term with the Janus kinase inhibitor ruxolitinib.

Results of a clinical trial show that an axillary lymph node dissection can be avoided for patients with large, operable tumors in the breast, no clinical signs of cancer in the axillary nodes before being treated with neoadjuvant chemotherapy, and no signs of cancer following a sentinel lymph node biopsy during surgery.

The FDA has approved rucaparib (Rubraca) as a treatment for patients with BRCA-positive advanced ovarian cancer who have received at least 2 prior lines of chemotherapy, according to Clovis, the manufacturer of the PARP inhibitor

A third of patients with previously treated, high- and intermediate-risk myelofibrosis had objective responses to the investigational Second mitochondria-derived activator of caspases mimetic LCL161.

An analysis of c-MYC expression in relapsed myeloma identified subgroups of patients with improved response to the combination of an immunomodulator and a proteasome inhibitor.

Patients with newly diagnosed multiple myeloma had significant improvement in progression-free survival when treated with dual versus single autologous stem-cell transplant.

The Committee for Medicinal Products for Human Use has recommended approval of alectinib as a treatment for patients with metastatic ALK-positive non—small cell lung cancer following progression on crizotinib.

CMS and Rep. Nancy Pelosi (D-CA) have confirmed the demise of the Medicare Part B Drug Payment Model "experiment" to cut margins paid to physicians on some of the most expensive drugs and introduce private sector thinking into drug purchasing and pricing systems.

The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of frontline pembrolizumab for the treatment of patients with metastatic non–small cell lung cancer whose tumors do not harbor EGFR or ALK mutations.

After 2 years of reflecting on feedback from the medical community, the American Board of Internal Medicine has developed a new iteration of its Maintenance of Certification testing that it hopes will satisfy the needs of physicians.

Worldwide clinical experience with the JAK1/2 inhibitor ruxolitinib (Jakafi) in patients with myelofibrosis has yielded safety and efficacy data similar to results of a pivotal randomized trial.

A continuous low-dose of ribociclib demonstrated both preliminary activity and an acceptable safety profile when compared with an intermittent dose of ribociclib when combined with fulvestrant in the treatment of postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer.

The addition of daratumumab to standard-of-care regimens tripled the increase in conversion to negative minimal residual disease status in the treatment of patients with relapsed/refractory multiple myeloma.

Testing for BRCA1 methylation or mRNA silencing did not predict a better response to carboplatin over docetaxel in patients with advanced triple-negative or BRCA1/2 breast cancer.